Acrivon Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Acrivon Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($77.91M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($80.56M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($60.39M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($31.17M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($16.24M) | Mar 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($84.11M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($89.20M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($67.10M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($32.66M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($16.18M) | Mar 28, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.99M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $63.99M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $46.02M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $23.95M | Mar 28, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($63.67M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($65.67M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($42.64M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($30.12M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($13.98M) | Mar 28, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.67M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.77M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.29M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.17M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $238.0K | Mar 28, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.72M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $196.59M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $138.27M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $181.23M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $106.59M | Mar 28, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.20M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $19.80M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $17.07M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $10.75M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $7.88M | Mar 28, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.52M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $176.79M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $121.20M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $170.48M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | ($23.81M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($8.41M) | Mar 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($274.88M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($196.98M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($116.42M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($56.03M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($24.87M) | Mar 28, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.50M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $39.82M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $36.02M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $29.52M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $99.60M | Mar 28, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (7) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (9) | Mar 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (7) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (9) | Mar 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31.65M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 31.23M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 22.52M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 21.92M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 1.77M | Mar 28, 2023 |